As of November 6, 2026, Moderna, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 8, 2026 to September 30, 2026, naming 1 appointment. The latest filing names Michael McDonnell, appointed (Form 8-K, September 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Moderna, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Moderna, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-08 to 2026-09-30. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Moderna, Inc. files it.
Also on the record for Moderna, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 14.8% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G, by Capital World Investors | 5.6% of the class | 5%+ stakes | Source |
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 13.1% of the class | 5%+ stakes | Source |
| July 24, 2026 | Stake report, Schedule 13G/A, by BAILLIE GIFFORD & CO | 4.6% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 6.53% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G/A, by BAILLIE GIFFORD & CO | 5.3% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 10.6% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G, by FMR LLC | 7.2% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 3.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Moderna, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Moderna, Inc. and the records around it.
Moderna, Inc. elsewhere on the record
Companies that share a holder
- BAILLIE GIFFORD & CO also filed stake reports on 39 other companies: QXO, Inc. (Oct 2026), Reddit, Inc. (Oct 2026), Samsara Inc. (Oct 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Moderna, Inc.
Get an email when Moderna, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Moderna, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Moderna, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Moderna, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-30 | Reported | not named in the filing | 8-K, 2026-09-30 | ||
| 2026-07-08 | In | 2026-07-08 | 8-K, 2026-07-08 |
New leaders reset buying decisions — get the Full Report on Moderna, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Moderna, Inc., with the record behind each one.
Find candidates like senior executive at Moderna, Inc.Every change, in the filing's words
Reported
(b) and (c) On September 30, 2026, Moderna, Inc. ("Moderna" or the "Company") announced the appointment of Juan Andres as its Chief Operating Officer ("COO") effective October 5, 2026.
- In this newly created role, Mr. Andres will support the increasing scale and diversification of the Company and will report to Chief Executive Officer Stephane Bancel and serve on the Company's Executive Committee.
- Mr. Andres, 62, previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and Quality Officer from 2018 through 2022 and as its President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023.
- During his tenure, he led the build-out and unprecedented scale-up of Moderna's manufacturing capabilities, including the rapid expansion of the Company's global manufacturing network to support the production and supply of Moderna's COVID-19 vaccine.
- In connection with his employment with the Company as COO, and pursuant to the terms of his offer letter, dated September 3, 2026 (the "Offer Letter"), Mr. Andres will receive an initial annual base salary of $800,000.
- Mr. Andres will also be eligible for an annual cash bonus (commencing with a pro-rated bonus for 2026) with an annual incentive target of 90% of his annual base salary, based upon achievement of certain individual performance goals and/or company performance goals established by the Company.
Appointed: Michael McDonnell, effective 2026-07-08
(d) On July 6, 2026 , the Board of Directors (the "Board") of Moderna, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "Nominating and Corporate Governance Committee"), appointed Michael McDonnell to the Board, effective July 8, 2026.
- Mr. McDonnell has more than 35 years of financial leadership and public company experience, most recently serving as Chief Financial Officer of Biogen Inc. from August 2020 through February 2025.
- He previously served as Chief Financial Officer of IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications.
- Mr. McDonnell was appointed to serve as a Class II director of the Company, to hold office until the 2029 annual meeting of shareholders or until his earlier death, resignation or removal.
- Mr. McDonnell was also appointed to serve on the Audit Committee of the Board (the "Audit Committee").
- Simultaneously with Mr. McDonnell's appointment to serve on the Audit Committee, David Rubenstein ceased to serve as a member of the Audit Committee and was appointed to serve on the Nominating and Corporate Governance Committee.
- Pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Policy"), Mr. McDonnell will be eligible to receive the non-employee director compensation as described beginning on page 30 of the Company's proxy statement for the 2026 Annual Meeting filed with the U.S. Securities and Exchange Commission on March 16, 2026 (the "Proxy Statement").
- Mr. McDonnell will receive an Initial Grant and a pro-rata portion of an Annual Grant, each as defined in the Proxy Statement.
Tools for this story
Each opens in a new tab, filled in for Moderna, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.